DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results - Company will host a business update conference call on Tuesday

DelMar Pharmaceuticals Announces Second

Fiscal Year 2018 Financial Results

- Company will host a business update

conference call on Tuesday, February 20, 2018 at 4:30 PM EST -

VANCOUVER, British Columbia and MENLO

PARK, Calif., February 14, 2018 /PRNewswire/ - DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar"

or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial

results for the second quarter ended December 31, 2017. DelMar executive management will host a business update conference call

for investors, analysts and other interested parties on Tuesday, February 20, 2018 at 4:30 p.m. Eastern Standard Time.

"This quarter has been an exciting

period for DelMar. Our priority is to leverage VAL-083's unique mechanism of action to efficiently advance it into the most

promising indications, including MGMT-unmethylated glioblastoma and platinum-resistant ovarian cancer. We now have a revised VAL-083

development strategy that is focused on MGMT methylation status in glioblastoma, which has become routine in clinical practice

as a biomarker which correlates with resistance to the standard-of-care chemotherapy with temozolomide (Temodar "TMZ"),

and patient outcomes. We believe using this biomarker will allow us to optimize patient selection for treatment with our lead drug

candidate, VAL-083, thereby streamlining development and enhancing opportunities for success in our clinical development programs,"

commented Saiid Zarrabian, Interim President and Chief Executive Officer.

AND UPDATED STRATEGIC PLAN

further details on the Company's operating and financial results, as well as more detail about its updated strategy,

refer to DelMar's 10-Q filed with the SEC on February 14, 2018, http://ir.delmarpharma.com/all-sec-filings.

CONFERENCE CALL DETAILS

DelMar plans to host a conference call

to discuss its financial results for the quarter ended December 31, 2017 and provide a corporate update on Tuesday, February 20,

2018, at 4:30 p.m. Eastern Time. For both "listen-only" participants and those who wish to take part in the question

and answer portion of the call, the telephone Dial-in Number is 1 888 632 3384 (toll free) with Conference ID DELMAR.

A replay of the conference call will be

available on the IR Calendar of the Investors section of the Company's website at www.delmarpharma.com

and will be archived for 30 days.

SUMMARY OF FINANCIAL RESULTS FOR THE PERIOD ENDED DECEMBER

At December 31, 2017, the Company had cash

and clinical trial deposits on hand of approximately $12.0 million (unaudited).

For the three months ended December 31,

2017, the Company reported a net loss of $3,161,598 or $0.14 per share, compared to a net loss of $1,321,973, or $0.13 per share,

for the three months ended December 31, 2016. For the six months ended December 31, 2017, the Company reported a net loss of $5,828,004

or $0.31 per share, compared to a net loss of $3,612,312, or $0.36 per share, for the six months ended December 31, 2016.

The following represents selected financial

information as of December 31, 2017. The Company's financial information has been prepared in accordance with U.S. GAAP and

this selected information should be read in conjunction with DelMar's consolidated financial statements and management's

discussion and analysis ("MD&A"), as filed.

DelMar's financial statements as filed with the U.S.

Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings.

Selected Balance Sheet Data

Selected Statement of Operations Data

For the three months ended:

Excluding the impact of non-cash expense,

research and development expenses increased to $2,015,570 during the current quarter compared to $1,186,637 for the same period

in the prior year. The increase was largely attributable to an increase in clinical development costs related to the three clinical

studies ongoing for VAL-083, as well as personnel, and preclinical research costs. Excluding the impact of non-cash expenses, general

and administrative expenses increased in the quarter ended December 31, 2017 to $909,747 from $580,761 for the quarter ended December

For the six months ended:

Excluding the impact of non-cash expense,

research and development expenses increased to $3,955,187 during the six months ended December 31, 2017 compared to $1,863,529

for the same period in the prior year. The increase was largely attributable to VAL-083 clinical development and manufacturing

costs related to the Company's STAR-3 refractory-GBM clinical trial and two Phase 2 clinical trials in MGMT-unmethylated

Excluding the impact of non-cash expenses,

general and administrative expenses increased in the current six months to $1,586,005 compared to $1,307,175 for the six months

ended December 31, 2016.

We believe, based on our current estimates,

that we will be able to fund our operations into the second quarter of calendar year 2019.

Pharmaceuticals, Inc.

DelMar Pharmaceuticals is focused on the

development and commercialization of new therapies for cancer patients who have limited or no treatment options. By focusing on

understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies

in indications where patients are failing, or have become intolerable to, modern targeted or biologic treatments.

The Company's current pipeline is

based around VAL-083, a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated

clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder

cancer, head & neck) in U.S. clinical trials sponsored by the NCI. Based on DelMar's internal research programs and these

prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization

of VAL-083 across multiple oncology indications to solve significant unmet medical needs.

VAL-083 is also being studied in two collaborator-supported,

biomarker driven, Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant

unmet medical need in the treatment of GBM. DelMar also recently announced the allowance of a separate IND for VAL-083 as a potential

treatment for platinum-resistant ovarian cancer.

Further information on DelMar's

clinical trials can be found on clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For further information, please visit

http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Connect with the Company on Twitter, LinkedIn,

Facebook, and Google+.

Safe Harbor Statement

contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current

expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ

materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability

to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and

technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research

and development, clinical studies and future product commercialization; and, the Company's business, research, product development,

regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more

detail in the Company's filings with the SEC, including, the Company's Annual Report on Form 10-K for the year ended

June 30, 2017, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K.